Clinical characteristics and pathogenic analysis of lower respiratory tract infections in advanced lung cancer patients with different treatment modalities

Abstract

Objective: To clarify the clinical characteristics and pathogenic analysis after lower respiratory tract infection in patients with advanced lung cancer under different treatments.

Methods: A retrospective analysis was adopted to collect 94 cases of patients with advanced lung cancer combined with lower respiratory tract infection from January 1, 2018 to December 1, 2020. Seventy-four cases were male and 20 cases were female. According to the different treatments, the patients were divided into 43 cases in the chemotherapy group and 51 cases in the chemoradiotherapy group. The pathogenic and serological indexes were compared between the two groups to provide ideas for the application of antibiotics.

Results: In the comparison of general clinical data, the chemotherapy group had a shorter hospital stay than the chemoradiotherapy group and a higher body mass index level than the chemoradiotherapy group (p < 0.05). In the comparison of serological indicators, procalcitonin, high-sensitive C-reactive protein, erythrocyte sedimentation rate, and neutrophil percentage were lower in the chemotherapy group, and the lymphocyte was higher than that in the chemoradiotherapy group (p < 0.05). There was no difference in hemoglobin, albumin, creatinine, and alanine transaminase between the two groups (p > 0.05). In the comparison of pathogenicity, the chemotherapy group was more likely to have combined viral infections, while the chemoradiotherapy group was more likely to have Gram-negative bacterial infections (p < 0.05). There was no difference between the two groups in terms of fungal infections (p > 0.05). Besides, the chemoradiotherapy group was more likely to have combined infections (p > 0.05).

Conclusion: Patients with advanced lung cancer treated with chemoradiotherapy have a relatively poor prognosis after developing lower respiratory tract infections and are more likely to have mixed infections. Antibiotics need to be applied as early as possible. The common pathogens should be covered. Antiviral and antifungal drugs can be added as appropriate, and drug sensitivity tests should be completed as early as possible.

Keywords

chemoradiotherapy / chemotherapy / advanced lung cancer / pathogen

References

[1] World Health Organisation (WHO). The top 10 causes of death. WHO; 2020. Accessed December 9, 2020. Available from the website of World Health Organization.

[2] World Health Organisation (WHO). Latest global cancer data. GLOBOCAN database 2020. WHO; 2020. Accessed December 10, 2020. Available from the website of World Health Organization.

[3] Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med. 2013; 137 (9): 1191- 1198.

[4] Cheung CHY, Juan HF. Quantitative proteomics in lung cancer. J Biomed Sci. 2017; 24 (1): 37.

[5] Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012; 13 (7): 671- 678.

[6] Shiono A, Imai H, Wasamoto S, et al. Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. Cancer Med. 2023; 12 (1): 73- 83.

[7] Kobayashi AK, Horinouchi H, Nakayama Y, et al. Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: a consecutive analysis of 38 patients. Lung Cancer. 2020; 145: 105- 110.

[8] Baburaj G, Thomas L, Rao M. Potential drug interactions of repurposed COVID-19 drugs with lung cancer pharmacotherapies. Arch Med Res. 2021; 52 (3): 261- 269.

[9] Honda Y. [Lung cancer and respiratory infections]. Gan To Kagaku Ryoho. 2020; 47 (5): 750- 753.

[10] Benveniste MF, Welsh J, Viswanathan C, et al. Lung cancer: posttreatment imaging: radiation therapy and imaging findings. Radiol Clin North Am. 2018; 56 (3): 471- 483.

[11] 中国临床肿瘤协会指南工作委员会组织. 中国临床肿瘤协会 （CSCO）小细胞肺癌指南‐2021[M].北京:人民卫生出版社; 2021.

[12] 临床微生物标本采集和送检指南[J]. 中华医院感染学杂志. 2018, 28 (20): 3192- 3200.

[13] 成人呼吸系统感染性疾病病原学诊断专家意见[J]. 中华结核和呼吸杂志. 2020; 43 (9): 757- 764.

[14] Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021; 375: n2363.

[15] Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med. 2021; 21 (1): 9.

[16] Bielopolski D, Evron E, Moreh-Rahav O, Landes M, Stemmer SM, Salamon F. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother. 2017; 29 (2): 113- 117.

[17] Park YH, Kim JS. Predictors of radiation pneumonitis and pulmonary function changes after concurrent chemo-radiotherapy of non-small cell lung cancer. Radiat Oncol J. 2013; 31: 34- 40.

[18] Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013; 85 (2): 444- 450.

[19] Vogelius IR, Bentzen SM. A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol. 2012; 51 (8): 975- 983.

[20] Hespanhol V, Bárbara C. Pneumonia mortality, comorbidities matter? Pulmonology. 2020; 26 (3): 123- 129.

[21] Ho JC, Leung CC. Management of co-existent tuberculosis and lung cancer. Lung Cancer. 2018; 122: 83- 87.

[22] Rolston KVI. Polymicrobial pulmonary infections in cancer patients with underlying solid tumors. Infection. 2017; 45: 245- 246.

[23] Rolston KVI, Jamal MA, Nesher L, Shelburne SA, Raad I, Prince RA. In vitro activity of ceftaroline and comparator agents against Gram-positive and Gram-negative clinical isolates from cancer patients. Int J Antimicro Ag. 2017; 49: 416- 421.

[24] Aitken SL, Tarrand JJ, Deshpande LM, et al. High rates of nonsusceptibility to ceftazidime-avibactam and identification of New Delhi metallo-β-lactamase production in Enterobacteriaceae bloodstream infections at a major cancer center. Clin Infect Dis. 2016; 63: 954- 958.

[25] Rolston KVI, Nesher L. Post-obstructive pneumonia in patients with cancer: a review. Infect Dis Ther. 2018; 7 (1): 29- 38.

RIGHTS & PERMISSIONS

2023 2023 The Authors. Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.